Kazia Therapeutics Reports EVT801 Clinical Findings at 15th Biennial Ovarian Cancer Research Conference.

Arrowhead Pharmaceuticals Seeks Approval to Start Phase 1/2a Trial of ARO-INHBE for Obesity Treatment.

Final Overall Survival Results of Datopotamab Deruxtecan in Metastatic HR-Positive, HER2 Low/Negative Breast Cancer from TROPION-Breast01 Phase 3 Trial Announced.

UCB reveals that BIMZELX[®] (bimekizumab-bkzx) has been approved by the U.S. FDA for treating psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.

Henlius and Intas get Positive CHMP Opinion for HETRONIFLY® (marketed as HANSIZHUANG in China) in Europe for first-line treatment in adults with extensive-stage small cell lung cancer.

Ipsen's Iqirvo® (elafibranor) receives European Union approval as the first new therapy for primary biliary cholangitis in almost ten years.

The European Commission Approves Astellas' VYLOY™ (zolbetuximab) with Chemotherapy for Advanced Stomach and Gastroesophageal Junction Cancer.

The U.S. Food and Drug Administration has greenlit Miplyffa (arimoclomol), an oral drug designed for managing Niemann-Pick disease type C (NPC).

OPUVIZ has received a recommendation for approval for adult patients in the treatment of neovascular (wet) age-related macular degeneration (AMD).

Tolebrutinib showed a 31% delay in the onset of confirmed disability progression in a phase 3 study of non-relapsing secondary progressive multiple sclerosis.

Tectonic Therapeutic Shares Positive Safety, Tolerability, and PK/PD Phase 1a Results for Lead Candidate TX45.

Trishula Therapeutics' Phase 1 trial of TTX-030 shows encouraging results for first-line treatment of metastatic pancreatic cancer.